Rationale and design of the Web-basEd soCial media tecHnology to improvement in Adherence to dual anTiplatelet Therapy following Drug-Eluting Stent Implantation (WECHAT): protocol for a randomised controlled study. Issue 1 (7th January 2020)

• Record Type: Journal Article
• Authors: Sun, Guo-li; Lei, Li; Liu, Liwei; Liu, Jin; He, Yibo; Guo, Zhaodong; Dai, Xiaohua; He, Lihao; Chen, Shi-qun; Liang, Yan; Ye, Jianfeng; Hu, Yunzhao; Chen, Guoqin; Chen, Ji-yan; Liu, Yong
• Is Part Of: BMJ open. Volume 10:Issue 1(2020)
• Publication Date: 2020-01-07
• Subjects: mobile health -- discontinuation rate -- dual antiplatelet therapy; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2019-033017
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Background: Dual antiplatelet therapy (DAPT) is frequently discontinued after drug-eluting stent (DES) implantation, which could increase the risk of major adverse cardiovascular events (MACEs). Few studies have attempted to improve DAPT adherence through web-based social media. Objective: To explore the effect of social media on DAPT adherence following DES implantation. Methods/design: The WeChat trial is a multicentre, single-blind, randomised study (1:1). It will recruit 760 patients with DES who require 12 months of DAPT. The control group will only receive usual care and general educational messages on medical knowledge. The intervention group will receive a personalised intervention, including interactive responses and medication and follow-up reminders beyond the general educational messages. The primary endpoint will be the discontinuation rate which is defined as the cessation of any dual antiplatelet drug owing to the participants' discretion within 1 year of DES implantation. The secondary endpoints will include medication adherence and MACEs. Both groups will receive messages or reminders four times a week with follow-ups over 12 months. Ethics and dissemination: Ethical approval was granted by Ethics Committee of Guangdong Provincial People's Hospital (GDREC2018327H). Results will be disseminated via peer-reviewed publications and presentations at international conferences. Trial registration number: NCT03732066